246 related articles for article (PubMed ID: 32248662)
21. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
22. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
23. Sample size adjustment designs with time-to-event outcomes: A caution.
Freidlin B; Korn EL
Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
[TBL] [Abstract][Full Text] [Related]
24. Group sequential designs for stepped-wedge cluster randomised trials.
Grayling MJ; Wason JM; Mander AP
Clin Trials; 2017 Oct; 14(5):507-517. PubMed ID: 28653550
[TBL] [Abstract][Full Text] [Related]
25. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Roig MB; Melis GG; Posch M; Koenig F
Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
[TBL] [Abstract][Full Text] [Related]
26. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
Asakura K; Hamasaki T; Evans SR
Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
[TBL] [Abstract][Full Text] [Related]
27. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
28. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
Quan H; Xu Y; Liu Y; Chen X
Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
[TBL] [Abstract][Full Text] [Related]
29. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
Harden M; Friede T
Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
[TBL] [Abstract][Full Text] [Related]
30. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
Jörgens S; Wassmer G; König F; Posch M
Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
[TBL] [Abstract][Full Text] [Related]
31. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
[TBL] [Abstract][Full Text] [Related]
32. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
33. Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses.
Gu M; Lai TL
Control Clin Trials; 1999 Oct; 20(5):423-38. PubMed ID: 10503802
[TBL] [Abstract][Full Text] [Related]
34. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
35. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
36. A retrospective analysis of conditional power assumptions in clinical trials with continuous or binary endpoints.
Edwards JM; Walters SJ; Julious SA
Trials; 2023 Mar; 24(1):215. PubMed ID: 36949524
[TBL] [Abstract][Full Text] [Related]
37. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
Li X; Herrmann C; Rauch G
BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
[TBL] [Abstract][Full Text] [Related]
38. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
39. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
Żebrowska M; Posch M; Magirr D
Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
[TBL] [Abstract][Full Text] [Related]
40. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Rufibach K; Heinzmann D; Monnet A
Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
